NCT01037348View on ClinicalTrials.gov

Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Choroidal Neovascularisation
Interventions
DRUG

ranibizumab 0.5mg

Trial Locations (12)

BS1 2LX

Novartis Investigative Site, Bristol

EC1V 2PD

Novartis Investigational Site, City of London

NW1 5YE

Novartis Investigative Site, City of London

SE5 9RS

Novartis Investigative Site, City of London

GU16 7UJ

Novartis Investigative Site, Frimley

LS9 7TF

Novartis Investigative Site, Leeds

NE1 4LP

Novartis Investigative Site, Newcastle upon Tyne

NG5 1PG

Novartis Investigative Site, Nottingham

SO16 6YD

Novartis Investigative Site, Southampton

TQ2 7AA

Novartis Investigative Site, Torquay

WV10 0QP

Novartis Investigative Site, Wolverhampton

YO31 8HE

Novartis Investigative Site, York

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY